Watermark
  Back to Search Results

AdvanTIG-302

Terminated

A Study of Ociperlimab With Tislelizumab Compared to Pembrolizumab in Participants With Untreated Lung Cancer

BeOne Study ID Info icon SVG graphic used for tooltips or additional information.

AdvanTIG-302

ClinicalTrials.gov ID Info icon SVG graphic used for tooltips or additional information.

NCT04746924

EudraCT or EUCT Number Info icon SVG graphic used for tooltips or additional information.

2023-507317-10-00

China Drug Trials ID Info icon SVG graphic used for tooltips or additional information.

CTR20211476/CTR20211464

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Plain Language Summary Study Protocol Statistical Analysis Plan

Study Overview

Sex: All Info icon SVG graphic used for tooltips or additional information.

Age: 18 Years / N/A

Accepts Healthy Volunteers? No

Study Documents

Plain Language Summary Study Protocol Statistical Analysis Plan